IP Library Granted Patent US 8,002,843
Granted Patent B2
US 8,002,843 · App. 10/771,736 · Granted Aug 23, 2011

Polyurethanes for osteoimplants

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,002,843
App. No.
10/771,736
Granted
Aug 23, 2011
Kind
B2
Abstract

Biological-based polyurethanes and methods of making the same. The polyurethanes are formed by reacting a biodegradable polyisocyanate (such as lysine diisocyanate) with an optionally hydroxylated biomolecule to form polyurethane. The polymers formed may be combined with ceramic and/or bone particles to form a composite, which may be used as an osteoimplant.

Claims (39)

1. A biodegradable polyurethane composite, comprising:

a polyurethane matrix formed by reaction of a polyisocyanate with a hydroxylated biomolecule to form a biodegradable polyurethane polymer, wherein the biodegradable polyurethane polymer is cross-linked; and

a reinforcement embedded in the matrix, wherein the reinforcement comprises a material selected from the group consisting of bone and bone substitutes, wherein the polyurethane composite further comprises polycaprolactone.

2. The polyurethane composite of claim 1 , wherein the reinforcement comprises a material selected from the group consisting of calcium carbonate, calcium sulfate, calcium phosphosilicate, sodium phosphate, calcium aluminate, calcium phosphate, calcium carbonate, hydroxyapatite, demineralized bone, mineralized bone, and combinations thereof.

3. The polyurethane composite of claim 1 , wherein the polyisocyanate is a diisocyanate.

4. The polyurethane composite of claim 1 , wherein the polyisocyanate is selected from the group consisting of lysine diisocyanate, toluene diisocyanate, arginine diisocyanate, asparagine diisocyanate, glutamine diisocyanate, hexamethylene diisocyanate, hexane diisocyanate, methylene bis-p-phenyl diisocyanate, isocyanurate polyisocyanates, 1,4-butane diisocyanate, uretdione polyisocyanate, and aliphatic, alicyclic, and aromatic polyisocyanates.

5. The polyurethane composite of claim 1 , wherein the biomolecule is lecithin.

6. The polyurethane composite of claim 1 , further comprising one or more substances selected from a biomolecule, a bioactive agent, and a small molecule.

7. The polyurethane composite of claim 6 , wherein the substance is selected from the group consisting of lectins, growth factors, immunosuppressives, and chemoattractants.

8. The polyurethane composite of claim 1 , comprising at least 10 weight percent of the reinforcement.

9. The polyurethane composite of claim 1 , comprising at least 30 weight percent of the reinforcement.

10. The polyurethane composite of claim 1 , comprising at least 50 weight percent of the reinforcement.

11. The polyurethane composite of claim 1 , comprising at least 70 weight percent of the reinforcement.

12. The polyurethane composite of claim 1 , wherein the polyurethane composite has a wet compressive strength that exceeds the wet compressive strength of the polyurethane alone.

13. The polyurethane composite of claim 1 , wherein the polyurethane composite has a wet compressive strength of at least 3 MPa.

14. The polyurethane composite of claim 1 , wherein the polyurethane composite has a wet compressive strength of at least 10 MPa.

15. The polyurethane composite of claim 1 , wherein the polyurethane composite has a wet compressive strength of at least 50 MPa.

16. The polyurethane composite of claim 1 , wherein the polyurethane composite has a wet compressive strength of at least 75 MPa.

17. The polyurethane composite of claim 1 , wherein the polyurethane composite has a wet compressive strength of at least 100 MPa.

18. The polyurethane composite of claim 1 , wherein the polyurethane composite does not fail when subjected to at least 10 5 fatigue cycles at 3 MPa when wet.

19. The polyurethane composite of claim 1 , wherein the polyurethane composite does not fail when subjected to at least 10 6 fatigue cycles at 25 MPa when wet.

20. The polyurethane composite of claim 1 , wherein the polyurethane has a creep rate of less than 15% in 24 hours at 3 MPa when wet.

21. The polyurethane composite of claim 1 , wherein the polyurethane has a creep rate of less than 10% in 24 hours at 25 MPa when wet.

22. The polyurethane composite of claim 1 , wherein the polyurethane degrades at a rate sufficient to permit generation of new tissue at an in vivo implantation site.

23. The polyurethane composite of claim 1 , wherein the polyurethane degrades at a rate of about 5% of original composite weight per month when implanted in vivo.

24. The polyurethane composite of claim 1 , wherein the polyurethane degrades at a rate of about 10% of original composite weight per month when implanted in vivo.

25. The polyurethane composite of claim 1 , wherein the polyurethane degrades at a rate of about 25% of original composite weight per month when implanted in vivo.

26. The polyurethane composite of claim 1 , wherein the polyurethane has a maximum resolved shear strength of at least 3 MPa.

27. The polyurethane composite of claim 1 , wherein the polyurethane has a maximum resolved compressive strength of at least 3 MPa.

28. The polyurethane composite of claim 1 , wherein the polyurethane has a maximum resolved tensile strength of at least 3 MPa.

29. A biodegradable polyurethane composite, comprising:

a polyurethane matrix formed by a reaction of a polyisocyanate with a biomolecule to form a biodegradable polyurethane polymer, wherein the biodegradable polyurethane polymer is cross-linked; and

a reinforcement embedded in the matrix, wherein the reinforcement comprises a material selected from the group consisting of bone and bone substitutes, wherein the polyurethane composite further comprises polycaprolactone.

30. The polyurethane composite of claim 1 , wherein the biomolecule is a phospholipid.

31. The polyurethane composite of claim 1 , wherein the biomolecule is a fatty acid.

32. The polyurethane composite of claim 1 , wherein the biomolecule is a cholesterol.

33. The polyurethane composite of claim 1 , wherein the biomolecule is a polysaccharide.

34. The polyurethane composite of claim 1 , wherein the biomolecule is a starch.

35. The polyurethane composite of claim 1 , wherein the biomolecule is a combination of biomolecules selected from the group consisting of a phospholipid, a fatty acid, a cholesterol, a polysaccharide, and a starch.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2011
From: OSTEOTECH, INC.
To: WARSAW ORTHOPEDIC, INC.
Reel/Frame 026196/0585 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2004
From: KNAACK, DAVID; WINTERBOTTOM, JOHN; KAES, DAVID; BOYCE, TODD; SHIMP, LAWRENCE A.
To: OSTEOTECH, INC.
Reel/Frame 015997/0634 →